Peer-reviewedCC BY-NC-SASingapore Medical Journal
Alzheimer’s disease: from breakthroughs to real-world impact
Related
- Spatial patterns of amyloid clearance after donanemab: A preliminary 12‐month real‐world amyloid PET study in Japanese patients with early Alzheimer's disease
- Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis
- Real‐world clinical, biomarker, and imaging outcomes of lecanemab in Alzheimer's disease: a multicenter longitudinal cohort study in Jiangsu, China
- Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.
- Communication and shared decision‐making for anti‐amyloid therapy in early Alzheimer's disease: An exploratory qualitative study of real‐world audio‐recorded clinical encounters
BibTeX
@article{lifengtan2026alzheimers,
title = {{Alzheimer’s disease: from breakthroughs to real-world impact}},
author = {Li Feng Tan, FAMS and Yao Feng Chong, MRCP and Adeline SL Ng, MB ChB, MRCP (UK) and Tau Ming Liew, PhD and Philip LK Yap, MRCP},
journal = {Singapore Medical Journal},
year = {2026},
month = sep,
doi = {10.4103/singaporemedj.smj-2026-466},
url = {https://doi.org/10.4103/singaporemedj.smj-2026-466},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Alzheimer’s disease: from breakthroughs to real-world impact
AU - Li Feng Tan, FAMS
AU - Yao Feng Chong, MRCP
AU - Adeline SL Ng, MB ChB, MRCP (UK)
AU - Tau Ming Liew, PhD
AU - Philip LK Yap, MRCP
PY - 2026
DA - 2026/09/01
JO - Singapore Medical Journal
DO - 10.4103/singaporemedj.smj-2026-466
UR - https://doi.org/10.4103/singaporemedj.smj-2026-466
SN - 0037-5675
SN - 2737-5935
ER -